The combination of lenvatinib with other targeted agents, such as mTOR inhibitors [43–45], is a promising area of investigation, while MEK inhibitors, BRAF inhibitors [37, 38] and immune-oncology agents [46] also show promise for treating radioiodine-refractory, differentiated thyroid cancer. This evidence concerns the gene MAP2K7 and differentiated thyroid carcinoma.